1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs (NIH) is sponsored by National Institutes of Health (NIH). The NIH SBIR/STTR programs offer non-dilutive funding for early-stage research and development in life sciences.
The National Institute on Minority Health and Health Disparities (NIMHD) specifically encourages entrepreneurs from all backgrounds with product ideas and concepts whose potential commercialization supports the NIH research mission to apply. This could include manufacturing aspects of biomedical innovations.
Get alerted about grants like this
Save a search for “National Institutes of Health (NIH)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) | National Institute of General Medical Sciences NIH has congressionally mandated set-aside programs for U.S. small businesses to engage in research and development activities that have strong potential for commercialization. Awards are intended to: Stimulate technological innovation. Use small business to meet federal research and development needs.
Increase private sector commercialization of innovations derived from federal research and development. The NIH SBIR/STTR program consists of two phases: Phase 1 (R41/R43) establishes the scientific and technical merit and feasibility as well as the potential for commercialization of the proposed Phase 2 (R42/R44) continues research or research and development (R&D) efforts initiated in Phase 1.
NIH SBIR/STTR grant solicitation announcements and additional information are website. You can also find information on the difference between SBIR and STTR application requirements . NIGMS-Specific SBIR Guidance The goal of NIGMS is to support innovative SBIR projects that could benefit the research communities related to its mission.
SBIR/STTR grant applications are accepted in most of the scientific areas for which the Institute provides support. Specific topics of research interest to NIGMS [PDF] . The NIGMS SBIR program like the vast majority of NIGMS-funded research is investigator-initiated.
Applicants propose what to do, how to do it, and the best path toward commercialization. NIGMS will not accept applications with budget requests exceeding the statutory budget limitations defined in the specific SBIR/STTR notice of considered to fit one or more of the SBA-approved topics for awards over the statutory budget limitations listed in SBA-Approved Waiver Topics of the SBIR/STTR Program Descriptions and Topics .
Applicants who are considering a project with a budget exceeding the hard budget cap defined in the notice of funding opportunity should contact the NIGMS SBIR coordinator early in the process of application preparation and at least six weeks prior to the anticipated submission due date. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
NIGMS support of Phase 2B competing renewal grant applications is limited and should be discussed in advance with the NIGMS SBIR coordinator. NIGMS does participate in the Commercialization Readiness Pilot (CRP) program designed to facilitate the transition of previously funded SBIR and STTR Phase 2 and Phase 2B projects to the commercialization stage by providing additional support for technical assistance.
List of NIGMS funding announcements (program announcements, requests for applications and notices) for the SBIR For information about NIGMS SBIR/STTR grants administration and management, NIGMS_GAB_SBIR@nigms. nih. gov .
NIH Research Evaluation and Commercialization Hub (REACH) The NIH Research Evaluation and Commercialization Hub (REACH) program was established to facilitate and accelerate the translation of academic biomedical discoveries into products that improve patient care and public health. Through this program, NIH will provide the qualifying institutions with the funds to seed the creation of academic entrepreneurship Hubs.
Hubs will be responsible for providing innovators with both the initial investment and resources to support the proof-of-concept work and the mentorship in product development and commercialization needed to develop high priority technologies within the NIH’s mission. For more information REACH and current For information about NIGMS SBIR programs, email Eddie Billingslea, Ph. D.
This page last updated on
Based on current listing details, eligibility includes: Qualified U.S. small businesses engaging in research and development with potential for commercialization. NIMHD prioritizes applications targeting the NIH Minority Health and Health Disparities Strategic Plan and Research Framework. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies, with some topics allowing larger awards with a waiver from SBA Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is March 10, 2025. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
NIH NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) is a grant from the National Institutes of Health (NIH) / National Cancer Institute (NCI) that funds early-stage postdoctoral researchers in cancer-related fields to transition to independent research careers. The award provides a mentored phase (K99) followed by an independent phase (R00), supporting investigators who do not require an extended period of supervised training beyond their doctoral degrees. Eligible applicants must hold a research or clinical doctoral degree and be postdoctoral fellows who have not yet established independent research careers. The March 11, 2026 due date applies; award amounts vary by project.
NIH R25 Summer Research Education Experience Program is a grant from the National Institutes of Health (NIH) that funds universities and institutions of higher education to provide summer research experiences in environmental health sciences to high school students, college undergraduates, and science teachers. Administered through the National Institute of Environmental Health Sciences (NIEHS), the program aims to attract young people to scientific careers and help teachers communicate about the scientific process more effectively. Eligible applicants are U.S. institutions eligible for NIH grants. The application deadline was March 17, 2026.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.